510(k) · Cleared
ClearedPremier Type Specific HSV-1 Igg Elisa Test
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Meridian Diagnostics, Inc. · MXJ Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-1
Cleared on Jun 25, 1999 after a 203-day review. The FDA summary names its predicate without a number.
- Decided
- Jun 25, 1999
- Review
- 203 days
- Class
- Class II
- Product code
- MXJ
- Recalls
- None
- Predicates
- 0
The FDA summary names its predicate without a number.
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in MXJ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new MXJ device
- #1 K213987 ARCHITECT HSV-1 IgG, ARCHITECT HSV-1 IgG…score 6.0 · 1 generation · no Class I recall
- #2 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | — | HSV-1 IgG ELISA Test Named without a submission number |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
How does its category compare?
All MXJ devicesMXJ Enzyme Linked Immunosorbent Assay, Herpes Simplex Virus, Hsv-1: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · MXJ
1in 2023
2026 to Oct 25, outlined.
Median 510(k) review, days · MXJ
123in 2007
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · MXJ
No recall names MXJ since 2007.
Adverse event reports per year · MXJ
1in 2025
MAUDE reports naming product code MXJ, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 3 | 123 | 0 | 1 |
| 2008 | 2 | — | 0 | 0 |
| 2009 | 1 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 1 | — | 0 | 0 |
| 2012 | 2 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 1 | — | 0 | 1 |
| 2015 | 1 | — | 0 | 0 |
| 2016 | 1 | — | 0 | 2 |
| 2017 | 0 | — | 0 | 1 |
| 2018 | 1 | — | 0 | 1 |
| 2019 | 0 | — | 0 | 1 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 2 |
| 2022 | 1 | — | 0 | 0 |
| 2023 | 1 | — | 0 | 140 |
| 2024 | 0 | — | 0 | 3 |
| 2025 | 0 | — | 0 | 1 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The PREMIER™ TYPE SPECIFIC HSV-1 IgG ELISA TEST is to be used in the testing of human serum specimens from individuals for whom the qualitative presence or absence of detectable IgG antibody to herpes simplex virus type 1 is warranted; specifically, when used in conjunction with the Premier™ Type Specific HSV-2 IgG ELISA Test in the screening of sexually active adults. This test is indicated for individuals at risk for a sexually transmitted HSV…
Read the full statement (148 words)
The PREMIER™ TYPE SPECIFIC HSV-1 IgG ELISA TEST is to be used in the testing of human serum specimens from individuals for whom the qualitative presence or absence of detectable IgG antibody to herpes simplex virus type 1 is warranted; specifically, when used in conjunction with the Premier™ Type Specific HSV-2 IgG ELISA Test in the screening of sexually active adults. This test is indicated for individuals at risk for a sexually transmitted HSV infection. For example, this test can clarify when an individual with symptoms suggestive of genital herpes has genital HSV-1 infection.
The PREMIER™ TYPE SPECIFIC HSV-1 IgG ELISA TEST is not recommended for use in a pediatric population. The performance characteristics of this device have not been established for testing patients with HSV-1 associated meningitis and encephalitis, prenatal and neonatal screening, the testing of immunosuppressed patients, or the detection of early stages of HSV seroconversion.
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K984343 · printed Nov 4, 2026
Cite this page
510(k) Report. “K984343: Premier Type Specific HSV-1 Igg Elisa Test.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K984343
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Page last updated Nov 3, 2026